Please try another search
For the nine months ended 31 March 2019, CerebainBiotech Corp revenues was not reported. Net loss decreased71% to $1.3M. Lower net loss reflects Loss fromextinguishment of debt decrease of 100% to $15K (expense),Selling, general and administrative expe decrease of 22% to$616K (expense), Research and development costs decrease of84% to $32K (expense). Basic Earnings per Share excludingExtraordinary Items increased from -$0.54 to -$0.09.
Period Ending: | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 |
---|---|---|---|---|
Total Revenue | 0 | 0 | 0 | 0 |
Gross Profit | ||||
Operating Income | -0.25 | -0.23 | -0.25 | -0.33 |
Net Income | -0.39 | -0.37 | -0.54 | -0.42 |
Period Ending: | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 |
---|---|---|---|---|
Total Assets | 0.02 | 0.03 | 0.06 | 0.09 |
Total Liabilities | 6.69 | 6.32 | 6.13 | 5.68 |
Total Equity | -6.66 | -6.29 | -6.07 | -5.58 |
Period Ending: | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 |
---|---|---|---|---|
Period Length: | 9 Months | 6 Months | 3 Months | 12 Months |
Cash From Operating Activities | -0.34 | -0.19 | -0.1 | -0.75 |
Cash From Investing Activities | ||||
Cash From Financing Activities | 0.29 | 0.14 | 0.07 | 0.8 |
Net Change in Cash | -0.05 | -0.05 | -0.03 | 0.05 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review